The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma

Cholangiocarcinoma (CCA) is one of the most difficult to treat cancers, and its nature of being largely refractory to most, if not all, current treatments results in generally poor prognosis and high mortality. Efficacious alternative therapies that can be used ubiquitously are urgently needed. Usin...

Descrición completa

Detalles Bibliográficos

Principais autores:	Orawan Suppramote, Sunisa Prasopporn, Satinee Aroonpruksakul, Ben Ponvilawan, Jiradej Makjaroen, Monthira Suntiparpluacha, Krittiya Korphaisarn, Komgrid Charngkaew, Rawisak Chanwat, Trairak Pisitkun, Seiji Okada, Somponnat Sampattavanich, Siwanon Jirawatnotai
Formato:	Artigo
Idioma:	Inglês
Publicado:	Frontiers Media S.A. 2022-05-01
Series:	Frontiers in Oncology
Assuntos:	acquired vulnerability ribosomal biogenesis stress CDK4/6 inhibitor oxaliplatin cholangiocarcinoma (CCA) palbociclib
Acceso en liña:	https://www.frontiersin.org/articles/10.3389/fonc.2022.877194/full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!